The dialysis service ecosystem in India is undergoing significant transformation, driven by various government and private sector initiatives aimed at improving access, affordability, and quality of care.
Certain of NephroPlus’ technology initiatives has enabled better monitoring of patient treatment which provide key insights to improve its offerings. For instance, as part of its product development capabilities, NephroPlus has developed Renova Dialyzer Reprocessing System, a cloud-enabled and globally patented dialyzer reprocessing system. Renova allows reuse of dialyzers for the same patient, and remote troubleshooting. This ensures treatment continuity, reduces downtime, and lowers maintenance costs.
Building on this, NephroPlus has launched “Pooja AI Dialysis Coach”, an AI-powered dialysis coach integrated with WhatsApp through the Business API. “Pooja AI Dialysis Coach” supports patients with diet tracking, nutrition advice, symptom support, and even image recognition to guide food choices. Offering 24/7 personalized assistance, it empowers patients to make informed daily decisions, improves awareness, and improving access to care.
Alongside “Pooja AI Dialysis Coach”, NephroPlus has built a suite of digital tools that streamline care delivery for both patients and providers. The Guest Application enables patients to access prescriptions, treatment bookings, health tips, and medical records, serving as a one-stop platform for continuity of care.
The Nephrologist Application allows doctors to update prescriptions, track patient progress, conduct video consultations, and review transparent payout histories. Complementing these are in-clinic applications that monitor vital parameters, treatments, and medications in real time. With centralized oversight and algorithm-generated summaries, these applications strengthen quality assurance and enable data-driven clinical research.
NephroPlus’ technology focus also extends to its infrastructure. The company has transitioned to a fully cloud-native architecture, which enables automatic scalability, faster deployments, and greater cost efficiency. Its proprietary clinic management portal, integrated with Microsoft Dynamics and OCR engines, centralizes patient lifecycle management while automating enterprise functions such as finance, supply chain, and MIS. This combination ensures operational governance and efficiency, supporting growth across an expanding network of clinics.
Mr. Rohit Singh, Group Chief Executive Officer, Nephrocare Health Services Limited, said: “At NephroPlus, technology is the backbone of how we manage scale. Today, monitoring the performance and quality of care across our clinics worldwide is possible because of the robust digital platforms we have built. From our proprietary clinic management portal to centralized quality dashboards, we are able to track patient outcomes, treatment parameters, and operational efficiency in real time. This level of visibility and standardization ensures that every patient—no matter which country they are in—receives the same standard of dialysis care.
In addition, NephroPlus leverages AI and predictive analytics to identify high-risk patients, trigger timely interventions, and optimize clinical outcomes. Proprietary dashboards allow staff to track a wide range of clinical parameters, from water quality to quality-of-life measures like EQ-5D. By turning this data into actionable insights, NephroPlus is building a system of continuous learning and improvement that directly benefits patient care.
As the dialysis sector develops further, NephroPlus’ use of technology and AI highlights one approach to strengthening dialysis delivery. From reprocessing with Renova to expanding access through “Pooja AI Dialysis Coach”, and from cloud-based infrastructure to predictive care tools, the company’s model demonstrates how digital solutions can be applied to scale operations while aiming to maintain standards of care across locations.
Disclaimer:
Nephrocare Health Services Private Limited (the “Company”) is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its equity shares and has filed a draft red herring prospectus dated July 25, 2025 (“DRHP”) with the Securities and Exchange Board of India (SEBI”). The DRHP is available on the websites of our Company, at https://nephroplus.com/, SEBI at www.sebi.gov.in as well as on the websites of the book running lead managers, ICICI Securities Limited, Ambit Private Limited, IIFL Capital Services Limited (formerly known as IIFL Securities Limited) and Nomura Financial Advisory and Securities (India) Private Limited, at www.icicisecurities.com, www.ambit.co, www.iiflcap.com and www.nomuraholdings.com/company/grou p/asia/india/index.html, respectively, and the websites of the stock exchange(s) at www.nseindia.com and www.bseindia.com, respectively. Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see “Risk Factors” of the RHP, when available. Potential investors should not rely on the DRHP for any investment decision.
Disclaimer – The above content is non-editorial, and ET Healthworld hereby disclaims any and all warranties, expressed or implied, relating to it, and does not guarantee, vouch for or necessarily endorse any of the content.
